Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Erie Indemnity Company's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $12.5B |
|---|
| Revenue (ttm) | 4.1B |
|---|
| Net income (ttm) | 577M |
|---|
| EPS (ttm) | $11.0 |
|---|
| Shares out | 52.3M |
|---|
| P/E (trailing) | 22.2x |
|---|
| P/E (forward) | 26.7x |
|---|
| Dividend | $5.85 (2.39%) |
|---|
| Volume | 127,947 |
|---|
| Beta | 0.33 |
|---|
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.63B | $2.84B | $3.27B | $3.80B | $4.07B | +11.5% |
| Gross profit | $2.70B | $376.2M | $520.3M | $676.5M | $640.8M | -30.2% |
| Operating income | $318.1M | $376.2M | $520.3M | $676.5M | $717.2M | +22.5% |
| Net income | $297.9M | $298.6M | $446.1M | $600.3M | $559.3M | +17.1% |
| EPS (diluted) | $5.61 | $6.08 | $8.69 | $11.49 | $12.24 | +21.5% |
| EBITDA | $-286.1M | $428.4M | $600.2M | $766.3M | $787.4M | — |
| R&D | $0 | $0 | $0 | — | — | +10.2% |
| SG&A | $58.3M | $668.3M | $737.1M | $806.3M | $74.1M | +6.2% |
Recent company headlines from major financial publishers.
In the base scenario, management fee revenue grows steadily in line with regional premium expansion while operating margins remain stable. Reinvestment moderates gradually, aligning intrinsic worth with Fair value $151.31 against the share price at analysis $239.05.
In the bull scenario, policyholder expansion into contiguous states accelerates while modern software deployments streamline administrative operations. Capital spending normalizes toward depreciation, releasing free cash flow and supporting Potential value $226.92.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | $188 | $206 | $230 | $267 | $327 |
| 6.0% | $158 | $168 | $180 | $197 | $220 |
| 7.0% | $138 | $144 | $151 | $161 | $172 |
| 8.0% | $123 | $127 | $132 | $138 | $145 |
| 9.0% | $112 | $115 | $118 | $122 | $127 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
